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Statements of significance  
This study places ERR at the interplay between the immune response and bone metastases of 
breast cancer, highlighting a potential target for intervention in advanced disease. 
 
Abstract (150 words)  
Bone is the most common metastatic site for breast cancer. Although the estrogen-related receptor 
alpha (ERR) has been implicated in breast cancer cell dissemination to the bone from the primary 
tumor, its role after tumor cell anchorage in the bone microenvironment remains elusive. Here, we 
reveal that ERR inhibits the progression of bone metastases of breast cancer cells by increasing 
the immune activity of the bone microenvironment. Overexpression of ERR in breast cancer bone 
metastases induced expression of chemokines CCL17 and CCL20 and repressed production of 
transforming growth factor beta 3 (TGF-3). Subsequently, CD8+ T lymphocytes recruited to bone 
metastases escaped TGF-signalingcontrol and were endowed with exacerbated cytotoxic 
features, resulting in significant reduction in metastases. The clinical relevance of our findings in 
mice was confirmed in over 240 breast cancer patients. Thus, this study reveals that ERR 
regulates immune properties in the bone microenvironment that contributes to decreasing 
metastatic growth.  
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Bone metastases (BM) are a frequent complication of cancer, occurring in up to 70 percent 
of patients with advanced breast cancer (BCa), and are associated with both high morbidity and 
elevated mortality (1)(2)(3). The progression of BM relies on the ability of the malignant cell 
colonizing the bone and to modify bone micro-environment allowing the release of bone-stored 
factors including transforming growth factor (TGF-), bone morphogenetic protein (BMP) or 
insulin growth factor (IGF), which in turn stimulate BM progression (2)(4). However treatments 
which mainly involved anti-resorptive agents of the bone failed to improve the overall survival of 
cancer patients even though it inhibited osteoclasts resorptive activity (3), implying that other 
mechanisms than the activation of osteoclasts by tumor cells are involved in modulating BM 
growth. The immune cells present in the bone, and particularly activated CD8
+ 
T lymphocytes can 
repress the progression of BCa osteolytic BM (5)(6)(7)(8). However, whether BM can influence 
the activation of immune cells present in the bone and by which mechanisms is totally unknown.  
The estrogen-related receptor alpha (ERR, or NR3B1 according to the Nuclear Receptors 
Nomenclature Committee, 1999) is over expressed in 55% of breast tumors (9)(10). Though 
ERRshares structural similarities with the estrogen receptors /, it does not bind estrogens and 
no natural ligand has yet been found (11), though several molecules can either increase or 
decrease ERR activity, such as the inverse-agonists XCT790 or C29 (12)(13). ERR is mainly 
involved in the adaptive bioenergetics response (11). In cancer, beside angiogenesis, ERR is 
strongly linked to tumor cell-invasion (14)(15). Notably, ERR-positive tumors are associated 
with more invasive BCa and a higher risk of recurrence (9)(14). The over-expression of ERR in 
BCa promotes tumor growth in the mammary gland and BCa metastatic dissemination to the bone 
(16). However, the role of ERRin BM outcome once they are anchorage in the bone 
microenvironment remains elusive.  
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In this study, using loss and gain of expression of ERR as well as chemical inhibitors, we 
demonstrated that ERR enhanced the ability of BCa cell established in the bone to recruit 
activated CD8
+ 
T cells to the bone. In addition, ERRexpression on BCa cells repressed their 
ability to produce TGF-a potent immune-suppressive cytokine. Subsequently, TGF- signaling 
was impaired in T cells infiltrating the bone, and CD8
+
 T cell cytotoxic function exacerbated 
leading to metastatic progression. Altogether, our work assigns a totally unexpected role to 
ERR revealing that the expression of this orphan receptor on the BCa metastases promotes an 
efficient anti-tumor immune response once the tumor cells are settled in bone. 
 
Materials and Methods 
Cell lines 
The mouse triple negative breast (TNBC) cancer cell line 4T1 (year 2012) (ATCC lot: 
58603185-CRL-2539) and human luminal MCF7 (year 2012) (ATCC-HTB-22 Lot: 86012803) 
were obtained from the American Type Culture Collection. MDA-MB-231/BO2-FRT (BO2) 
BCa cells, a subpopulation of the human MDA-MB-231 BCa line (TNBC) was selected for their 
high efficiency to metastasize to bone (17). These cell line was tested for authentication by DNA 
fingerprinting using short repeat (STR) method in 2014. TNBC cell lines and MCF7 were 
cultured in DMEM or RPMI-1640 (Life-Technologies) medium, respectively, supplemented 
with 10% fetal bovine serum (FBS, Perbio) and 1% penicillin/streptomycin (Invitrogen) at 37°C 
in a 5% CO2 incubator. Cells lines were tested for mycoplasma regularly. Mouse and human 
ESRRA ERR) and the dominant-negative co-activator domain AF2 (AF2) mutant were 
described previously (16)(18). Briefly, pSR-ERRWT and pEcmv-ERRAF2 or respective 
empty vectors (CT) constructs were transfected into parental 4T1 cells and cultured for 4 weeks 
in puromycin (2 g/mL) (Life-Technologies). Three independent clones were obtained from 
pSR-ERRWT transfection (4T1-ERR) and from pEcmv-ERRAF2 transfection (4T1-
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ERRAF2). Two independent clones were obtained from empty vectors transfection respectively 
pSR-4T1-CT (4T1-CT) and pEcmv-4T1-CT (4T1-CTaf2). For MCF7 clones, a mix containing 
1.5g Retroviral pLPCX-Human-ERRWT, pLPCX-HumanERRAF2 or empty vector and 
0.5g pCMV-VSV-G envelope vector (Cell-Biolabs) were used previously (16).  4T1-ERR and 
4T1-ERRAF2 (pool of 3clones each) cells were treated for 24 hours with the ERR -
agonists XCT790 (Sigma) or C29 (AGVdiscovery, France) at 1M and 5M, respectively, as 
described (13) (16) (19). DMSO was used as a vehicle (Veh).  
 
Animal studies 
6-week-old BALB/c female mice were purchased from Janvier (France) and housed in a SPF 
facility (ALECS platform (Faculté de Médecine Laennec, Lyon, France). BM experiments were 
performed by inoculating intra-arterially either 4T1-CT (pool of 2 clones) in parallel with 4T1-
ERR(pool of 3 clones), or 4T1-CT(af2) (pool of 2 clones) in parallel with 4T1-ERRAF2 
(pool of 3 clones) cell lines (5x10
5
 cells in 100 L of PBS). Radiographs (LifeRay HM Plus, 
Ferrania) of animals were taken at 15 days after inoculation using X-ray (MX-20; Faxitron X-ray 
Corporation). The extent of bone destruction for each animal was expressed in mm
2
. Animals 
were sacrificed and hind limbs were then collected for histology and histomorphometric 
analysis. Tibiae were scanned using microcomputed tomography (Skyscan1076, Skyscan, 
Belgium) with an 8.8 voxel size and an X-ray tube (50 kV; 80 mA) with 0.5 m aluminum filter 
and three-dimensional reconstructions were performed with a dedicated visualization software 
(NRecon&CTVox, and Skyscan) (18). Bone Volume/Tissue Volume: (%BV/TV) were carried 
out with CTAn (version 1.9, Skyscan) and CTVol (version 2.0, Skyscan) software. Dissected 
bones were then processed for histological (Goldner’s Trichrome solution staining) and 
histomorphometric analyses (tumor burden-to-soft tissue volume (%TB/STV)) (18). Depletion of 
CD8
+ 
T cells was performed by intra-peritoneal injection of anti-CD8 (BioXCell, clone Lyt3.2; 
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BE0223). 387.5 g per mouse were injected 4 times every two days, from day 10 after metastasis 
injection i.e when osteolytic lesions start to be detectable.  
Ethics statement 
Mice were handled according to the French Ministerial Decree No.87-848 of 19 October 1987. 
Experimental protocols were approved by the Institutional Animal Care and Use Committee at 
the Université-Lyon1 (France) (ethic committee CEEA-55 Comité d’Ethique en Expérimentation 
Animale-DR2014-44-DR2015-28). 
Human sample meta-genomic analysis  
Correlation analysis were performed using published datasets downloaded from the Gene-
Expression-Omnibus including primary tumor, no-metastases, Visceral+bone or only BM 
(GSE12276-GSE2034-GSE2603) (n=248) (20)(21)(22). Z-scores were calculated on normalized 
data of each dataset by subtracting the population mean from individual expression values for 
each gene and then dividing the difference by the population standard deviation. 
Sign arrays  
The expression levels of several chemokines known to influence T cell chemo-attraction were 
obtained by qPCR Sign Arrays (Cytokines Array and Inflammation Array). Indeed, two qPCR 
Sign Arrays: Cytokines and Inflammation Arrays (AnyGenes, CT1M1-IFM1)(CliniSciences) were 
used to quantify expression of cytokines, chemokines and growth factors. Total RNA was 
extracted from 4T1-CT and 4T1-ERR cells and 2 g were reverse-transcribed as previously 
described (16). Real-Time PCR was performed according to the manufacturer’s instructions. Two 
heat maps were generated using the heatmap.2 function in the gplots library of R (version 3.5.1). 
Only regulations that were reproducible between the two arrays are presented. 
Protein-protein interaction network reconstruction and analysis.  
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The protein-protein interaction network with BIOGRID (release 3.4.160) from Homo sapiens with 
PSICQUIC (Proteomics-Standard-Initiative-Common-QUery-InterfaCe) retrieval (10242018) and 
Cytoscape environment was used (16). A BIOGRID (https://thebiogrid.org/)-based custom 
approach was used to define a protein interactome of the following proteins: ESRRA-CCL17- 
CCL20-OPG-NRIP1-SRC1-SRC2-SRC3-PGC1A-PGC1B-CCR4 and CCR6. The resulting 
interactome encompasses 911 proteins (hereby defined as “Extended Network of ESRRA, 
CCL17, CCL20”) (reachable on Ndex webserver here) (Supplementary Fig.S1). To determine the 
connectors between CCL17, CCL20 and ESRRA, a custom approach combining shortest path and 
connectivity degree analysis was applied to determine a “Minimal Network of ESRRA, CCL17, 
CCL20” (reachable on Ndex webserver here) (containing 101 proteins) acknowledging 
connections that may support ESRRA signaling (Supplementary Fig. S2) (16). We overlaid and 
extracted information from the Gene-Ontology-consortium to pinpoint proteins that are already 
known to be involved in the immune system process, as well as T and B cell homeostasis (GO-
IDs: 0002376, 0043029, 0001782) to create “Minimal Network specific to immune response to 
tumor” (containing 52 proteins). To determine the connectors between ESRRA and CCL17, 
ESRRA and CCL20, a shortest path was applied to the “Minimal Network of ESRRA, CCL17 
and CCL20” (16)(23)(24).  
 
Ex vivo cell preparation 
For hind limbs, muscles were removed and bones were sliced, then incubated at 37°C with a 1/10 
solution of collagenase hyaluronidase (Stem cell) for 2 hours. Bones were then mechanically 
disrupted with a syringe plunge, filtered and cells were collected. For lung metastases (LM), 
lungs were crushed with a syringe plunge on a filter (100 m) (BD Bioscience) and cells were 
collected. Cells released from lungs and bones were incubated at 37°C in the presence of DMEM 
(Life Technologies) supplemented with 10% (v/v) fetal bovine serum (Perbio/Thermo Scientific) 
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and 6-thioguanine (Sigma A4882) (10 g/mL) for 2 weeks. The cells were then counted after 
being stained using Crystal Violet (RAL diagnostic 317980). 
Flow Cytometry 
Cells from spleen and lungs, obtained after mechanical disruption, and flushed bone marrow cells 
were pre-incubated with anti-CD16/32 (93 clone, Biolegend) and stained for surface marker for 30 
minutes at 4C with the following antibodies: anti-CD45 (30-F11 clone, BD or eBiosciences), 
anti-CD3e (145-2C11 clone, BD), anti-CD4 (GK1.5 clone, BD), anti-CD8 (53-6.7 clone, BD or 
eBiosciences), anti-CD19 (1D3 clone, BD), anti-CD11b (M1/70 clone, eBiosciences), anti-CD11c 
(N418 clone, eBiosciences), anti-CCR4 (2G12 clone Biolegend) anti-CCR6 (29-2217clone 
Biolegend), anti-Ly6C (AL21 clone, BD), anti-Ly6G (1A8 clone, BD), anti-F4/80 (BM8 clone, 
Biolegend), anti-CD107a (LAMP-1)(1D4B clone, BD), anti-FasL (MFL3 clone, eBiosciences). 
For cytokine production, cells were first incubated for 4 hours with PMA (P1585-1MG, Sigma), 
Ionomycin (I0634-1MG, Sigma) and Brefeldin A (00-4506-51, Life Technologies). Intracellular 
staining was performed with the Transcription Factor Staining Buffer Set (00-5523-00, 
eBiosciences), according to manufacturer’s recommendations. The following antibodies were 
used: anti-Foxp3 (R16-715 clone, BD), anti-IFN- (XMG1.2 clone, BD), anti-GzA (GzA-3G8.5 
clone, eBiosciences), anti-GzB (GB11 clone, Invitrogen), anti-Ki67 (11F6 clone Biolegend), anti-
pSMAD2/3 (D27F4 clone, Cell Signalling) coupled with anti-rabbit A488. CD8
+ 
T cell depletion 
was checked by flow cytometry on metastatic bone marrow and spleen using anti-CD8 (53-6.7 e-
Biosciences). Data were acquired on a LSR-II (BD Biosciences) and analyzed with the FlowJo 
software version X. 
Determination of ERR binding sites 
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The analysis of ERRbinding sites on TCA AGGTCA promoter regions was performed using the 
GTRD (“Gene Transcription Regulation Database”) that includes ChIP-seq data 
(http://gtrd.biouml.org/)(25).  
 
Chromatine immunoprecipitation (ChIP) 
ChIP assays were performed as previously described (16) from MDA-MB231-B02-CT and -
ERR cells (18) using either a monoclonal rabbit anti-ERR(13826)(Cell-Signaling) or a control 
rabbit IgG(2729) antibody (Cell-Signaling). The immune-precipitated genomic DNA was purified 
using NucleoSpin Clean-up colums (Macherey-Nagel,Germany) and analyzed by qPCR. 
Quantification of ChIP enrichment was calculated relative to input values. Distal and proximal 
elements of ERR gene were used as negative and positive controls respectively (26). 
Histology-Immunocytochemistry 
Tibia bearing metastases as well as lungs were fixed in 4% PFA (paraformaldehyde) (Antigenfix 
Diapath P0014), embedded in paraffin (Histowax Histolab 00403) then cut (5m sections) on a 
microtome (Microm HM 350S). Immunocytochemical analyses were performed by incubating 
tissue sections overnight with goat polyclonal antibody ERR (V-19, Santa Cruz) (1/40), rabbit 
polyclonal anti-human/mouse CCL17 (PA5-34515, ThermoFisher) (1/100), rabbit polyclonal anti-
mouse CCL20 (ab139585, Abcam) (1/100), rabbit polyclonal anti-human/mouse activated TGF-3 
(ab15537, Abcam) (1/100). Sections were then incubated with HRP-conjugated anti-mouse 
(K4000, Dako) and anti-rabbit (K4002, Dako) according to the manufacturer’s recommendations 
or anti-goat (sc2020, Santa Cruz)(1/300) antibodies for 1 hour and were detected using 3,3’-
diaminobenzidine (K3467, Dako) according to the manufacturer’s instructions. Counterstaining 
was performed using Mayer’s hematoxylin (Merck) according the supplier’s protocol. Lungs 
sections were made at three different depths for each mouse and stained with H&E. Metastasis 
counting was performed in double blind. 
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TUNEL assay 
Bone sections were deparaffinized and rehydrated followed by permeabilization with 0.2% triton 
(T9284, Sigma) and digestion with proteinase K (1g/mL) (K182001, ThermoFisher). For positive 
control, sections were incubated with DNAse I at 1mg/mL (Sigma, 11284932001). Sections were 
then incubated with biotin-16-dUTP (Sigma, 11093070910) and TUNEL enzyme (Sigma, 
11767305001) in deoxynucleotidyltransferase buffer (Tris-HCl 125mM (Euromedex, EU0011), 
sodium cacodylate 200mM (Sigma, C0250), BSA 6mM (Sigma, A7906), CoCl2 1mM (Sigma, 
15862-1ml-F)) at 37°C for 60 minutes in a humid atmosphere. Sections were washed in stop 
buffer (300mM NaCl (Sigma, S3014), 30mM NaC6H5O7-sodium citrate (Sigma, 71406)) and 
blocked with 2% BSA (Sigma, A7906). Sections were then labelled with streptavidin-
phycoerythrin (PE) (eBiosciences, 12-4317-87) and DAPI (Euromedex, 1050-A) and mounted 
with Fluoromount (Sigma, F4680-25ml) (upright microscope zeiss axioimager (sip 60549)). 
Real time RT-PCR  
Total RNAs from three independent batches of each clone of 4T1, MCF7 and B02 cell (CT, 
ERR and ERRAF2) were extracted with Trizol-reagent (Life-Technologies) and 2g were 
reverse-transcribed using qScript
TM
 cDNA SuperMix (Quanta-Biosciences). Real-time PCR was 
performed on a Mastercycler-ep-Realplex (Eppendorf) with primers specific to human and mouse 
genes (Supplementary Table S1) using Quantifast-SYBR-Green (Life-Technologies) according to 
the manufacturer’s instructions. The ribosomal protein RPL32 (L32) gene was used as a 





Data were analyzed statistically using either the non-parametric Mann-Whitney U test or unpaired 
t-test for in vivo studies (n = 10 mice for each group (bioStaTGV), unblinded studies). In vivo data 
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on bone were confirmed (n = 3) on smaller groups (n = 4). In vitro assays were repeated at least 
twice and performed on triplicate samples. Data were analyzed using ANOVA and paired Student 
t-test to assess the differences between groups. All data are presented as means ± SEM with 
similar variances between groups. Correlation scores for meta-analysis were calculated using the 
Pearson-correlation-coefficient. Statistical significance was determined by GraphPad Prism v5.02 
using the two-sided Student t-test. All statistical analyses were performed using the GraphPad 




ERR expression in BCa cells inhibits metastases growth in bones 
In order to assess the role of ERRin BCa cells after tumor cell-anchorage in the bone 
microenvironment, BALB/c mice were intra-arterially injected with first a pool of three 
independent 4T1 tumor cell clones over-expressing-ERR (4T1-ERR), and a pool of two 4T1 
tumor cell clones transfected with empty vector controls (4T1-CT) (16). Remarkably, fifteen days 
later, radiographic analysis revealed that animals bearing 4T1-ERRtumors had osteolytic lesions 
that were 70% smaller than those of mice bearing 4T1-CT tumors (9.39 ± 2.6 vs 3.08 ± 1.45 mm
2
) 
(Fig. 1A,B). The inhibitory effect of ERR on BCa cell growth was associated with mild bone 
destruction (Fig. 1C-E). Histological and histomorphometric analyses also demonstrated the 
limitation of BM progression when BCa cells over-expressed ERR (Fig. 1F,G). In clear contrast, 
when clones expressing a dominant-negative form (4T1-ERRAF2) with their respective controls 
clones (4T1-CTaf2) were injected later, we found a 60% increase in osteolytic lesions in animals 
bearing ERRAF2 tumors compared to control (4T1-CTaf2) mice (3.82 ± 1.99 vs 9.27 ± 2.064 
mm
2
) leading to their earlier sacrifice, prior 4T1-CT(af2) BM reach the percentage of osteolysis 
observed in 4T1-CT (Fig. 1H,I). Concomitantly, increased bone destruction and tumor burden 
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was observed (Fig. 1J-N). Given that 4T1 cells also colonize the lung (16), we analyzed the 
effects of ERR expression on the development of LM. As opposed to the bone, both numbers of 
LM and numbers of BCa colonies extracted from the lungs were independent of the expression 
levels of ERR in 4T1 cells (Fig. 2A-F). Of note, the ERRover-expression in LM was observed 
in animals bearing 4T1-ERRtumors compared to control groups (Fig. 2G). Taken together, this 
first set of data reveals that the over-expression of ERR in BCa cells prevents their growth in the 
bone, and suggests that ERRexpression in BCa may affect the bone microenvironment to 
prevent BM progression. 
 
ERR expression in BCa cells increases T cell anti-tumor response in the bone 
Given the importance of the immune response in the control of tumor growth, in particular 
metastases (5)(6)(7)(8), we next analyzed the effects of the expression of ERR by BCa cells on 
the bone immune system. It is worth noting that no significant effect was observed on innate cells 
including dendritic cells, macrophages, with the exception of slight decrease in neutrophils (15%) 
in the bone colonized by 4T1-ERR compared to 4T1-CT cells (Supplementary Fig. S3A-C). 
However, we found that metastatic legs of animals bearing 4T1-ERRtumors contained 5 times 
more T cells than those colonized with 4T1-CT cells (Fig. 3A). Moreover, in line with the larger 
4T1-CT BM observed (Fig. 1), which developed at the expense of the bone marrow that is largely 
depicted to sustain all stages of B cell medullary development (7)(8), the CD19
+
 compartment was 
4-5 times lower in mice bearing 4T1-CT BM compared to 4T1-ERRBM (Fig. 3A). Of note, T 
cell enrichment was neither observed in the lungs where 4T1-ERR cells were also anchored (Fig. 
3B), nor in the none invaded lymphoid organs such as the spleen (Supplementary Fig. S3 D,E), 
implying that the expression of ERR in BCa cells affected the T cell homeostasis after their 
anchorage in the bone. Interestingly, the increase in T cell proportion after 4T1-ERR cell bone 
settlement was largely restricted to the CD8
+
T lymphocyte compartment, with a 3.5-fold increase 
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in their number and percentage in bones bearing 4T1-ERRtumors compared to bone colonized 
with 4T1-CT cells (Fig. 3A), whereas the proportion of CD4
+
T cells in the bone, including that of 
Foxp3
+
 regulatory T (Treg) cells was unaffected (Supplementary Fig. S3C).  
In order to further characterize the CD8
+
 T cells over-represented in the bone after 4T1-
ERRcell colonization, we then analyzed their ability to produce cytotoxic molecules and 
cytokines. Strikingly, in bone colonized with 4T1-ERR cells, we found that CD8+ T cells 
expressed higher levels of FasL, Granzyme (Granz) A and B, in association with LAMP1 at their 
cell surface as well as IFN- whereas these molecules were barely detectable in CD8+ T cells from 
bones bearing 4T1-CT cells (Fig. 3C-E). In total agreement with this exacerbated cytotoxic 
program of CD8
+
 T in the presence of 4T1-ERR BCa cells in the bone, we found that a large 
fraction of 4T1-ERR BM underwent apoptosis compared to 4T1-CT cells (Fig. 3F,G). No 
exacerbated sign of cytotoxic activity was observed in the non-invaded spleen or in the metastatic 
lungs of mice bearing 4T1-ERR cells (Supplementary Fig. S4A). Importantly, the depletion of 
CD8
+
 T cells was sufficient (Fig. 4A) to increase 4T1-ERRBM progression (Fig. 4 B-E). This 
set of data suggests that the expression of ERRin BCa cells influences the CD8+ T cell 
homeostasis and increases their anti-tumor cytotoxic program in the bone allowing the control of 
the tumor progression. 
 
ERR expression leads to high levels of CCL17 and CCL20 production in BCa cells 
The aforementioned data strongly suggest that the expression of ERR by BCa cells 
influences the bone microenvironment to promote an efficient anti-tumor response. Interestingly, 
we failed to find any difference in Ki67 staining between CD8
+
T cells evolving with either 4T1-
CT or 4T1-ERRBM (Supplementary Fig. S4B), suggesting that ERRexpression affected T 
cell-recruitment to the bone rather than their proliferation in the bone. In order to address this 
hypothesis, we monitored the expression levels of several chemokines known to influence T cell 
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chemo-attraction and found a 2- and 3-fold up-regulation of Ccl17 and Ccl20 in 4T1-ERR cells, 
respectively (Fig. 5A,B, Supplementary Fig. S5A, Table S2). C29 or XCT-790 were sufficient to 
inhibit the over-expression of both Ccl17 and Ccl20, while no effect was observed in 4T1-
ERRAF2 cells ruling out any off-target effects (Fig. 5C-D; Supplementary Fig. S5B-C) (27), 
arguing in favour of a direct role for ERRin the control of the expression of these two 
chemokines (13). Of note, the ability of ERR to up-regulate Ccl17 and Ccl20 was also observed 
in other BCa cells including MCF7 and MDA-MB-231-B02 cells (Supplementary Fig. S5D-E) 
(16)(18). Interestingly, the up-regulation of CCL17 and CCL20, at both gene and protein levels 
due to ERR over-expression was sustained in 4T1-ERR BM (Fig. 5E,F) but lost in LM 
(Supplementary Fig. S5F). This data was reinforced following the analysis of ChIP-seq data 
revealing binding site for ERRin the promoter of Ccl17 and in Ccl20 (Supplementary Fig.S6A-
D).  
Given that CCL17 and CCL20 were reported to attract the fraction of activated CD8
+
 T 
cells expressing CCR4 and CCR6 (28), we next monitored the expression of both chemokine 
receptors on CD8
+
 T cells from the bone of animals bearing BM. In total agreement with the 
ability of 4T1-ERR cells to sustain their production of CCL17 and CCL20 in the bone, and the 
activated phenotype of CD8
+
 T cells (Fig. 3), we found that, in bone colonized by 4T1-ERR a 
large fraction of CD8
+
 T cells expressed either CCR4 or CCR6 or both (Fig. 5G). Thus, BCa 
cells over-expressing ERRare endowed with a unique ability to produce high amounts of 
CCL17 and CCL20 and efficiently recruit activated CD8
+
 T cells to the bone.  
ERR expression in BCa cellsreduces their TGF- production and decreases TGF- signaling 
in BM  
Since the cytotoxic program of CD8
+
T cells was largely exacerbated in legs bearing 4T1-
ERR cells, we next assessed the mechanisms by which ERR over-expression in BCa cells 
increased their cytotoxic function in the bone. To this end, we further investigated the connection 
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between CCL17-CCL20 and ERR (ESRRA) by choosing a global approach combining 
bioinformatic analyses of protein interaction networks and transcriptional regulator databases 
(Supplementary Fig. S1:extended network -S2:minimal network) (29). We created the “Minimal 
Network specific to immune response to tumor” (containing 52 proteins) (Fig. 6A) and by 
shortest path analysis, we then identified two new ESRRA-CCL17 or ESRRA-CCL20-
associated regulators: VCAM and TGF-3 (Fig. 6B,C). We and others reported that TGF- 
signalling in T cells inhibits the cytotoxic differentiation program of CD8
+
 T cells both in 
humans and mice (30)(31), we thus focused on this cytokine. The analysis of Tgf-3 expression 
revealed a 70% decrease in 4T1-ERR compared to 4T1-CT cells (Fig. 6D). Ex vivo bone 
cultures confirmed that ERRup-regulation in BCa cells negatively regulates Tgf-3 expression 
with a 55% decrease compared to control BCa BM (Fig. 6E). Strikingly, immunohistological 
staining revealed that the production of TGF-3 was largely decreased in BCa BM over-
expressing ERR (Fig. 6F). In agreement with the decrease of Tgf-3 expression in 4T1-ERR, 
we observed an increase in TGF-3 levels in 4T1-ERRAF2 BM (Fig. 6D) and a 5-fold increase 
in Tgf-3 expression after treatment of 4T1-ERR cells with the inverse agonist XCT-790 (Fig. 
6G). Similar results were observed in MCF7 and MDA-MB-231-B02 human cell lines (Fig. 
6H), ruling out an effect restricted to mouse 4T1 cells. Altogether these results reveal that the 
over-expression of ERR represses the expression of TGF- in BCa and could thus prevent the 
BCa BM from creating an immunosuppressive microenvironment provided by TGF- signal 
activation in immune cells.   
In order to unconditionally confirm that CD8
+
T cell evolving in 4T1-ERRcolonized 
bone escape TGF- signaling control, we next analyzed CD8+T cells from metastatic legs for the 
phosphorylation of SMAD2/3 proteins which translates specifically the TGF- signaling 
activation (32). Clearly, SMAD2/3 phosphorylation was 2-3 times lower compared to that of 
CD8
+
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recruitment to the bone, ERRover-expression in BCa cells impairs their ability to produce high 
amounts of TGF-, decreasing TGF- signaling in CD8+T cells, a key repressor of their 
cytotoxic activity and capacity to eliminate cancer cells. 
 
Over-expression of ESRRA (Err in patient tumours is associated with high levels of CCL17 
CCL20 and low levels of TGF- expression 
Finally, we addressed the relevance of our data obtained in mice to the human pathology. 
We performed a meta-analysis on 248 patients including luminal and triple-negative breast tumors 
(TNBC) split into four groups: all tumors (n = 248), patients without metastases (No Mets, n = 
121), patients that had visceral and bone metastases (Visceral+Bone metastases, n = 53) and 
patients that had only bone metastases (Bone Only, n = 74). As in mice, the ESRRA (Err 
expression was positively correlated with that of CCL17 and CCL20 and inversely proportional to 
that of TGF-in patients with metastases restricted to the bone (Bone Only) with luminal and 
TNBC tumors (Table 1A,B). Correlations were also identified in no-Mets, All, and Visceral 
+Bone groups of luminal or TNBC patients (Table 1A,B). In addition ERR expression was not 
associated with LM in two cohorts of BCa patients (16). Thus, this set of data from human sample 
analyses strongly suggests that, similarly to mice, the over-expression of ERRin human BCa 
cells allows them to create an immune-efficient environment in the bone by increasing the 
production of chemokines capable of attracting activated T cells to the bone and decreasing the 
production of TGF- essential for repressing the cytotoxic activity of T cells. 
 
Discussion 
Cancer cells adapt to the microenvironment, shaped by their own doing, which in turn influence 
their fate. This interplay is particularly important for cells forming metastases, which leave their 
primary microenvironment to settled in a new, second one. Here, we revealed that the level of 
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ERRexpression on BCa metastases promotes their ability to condition an efficient anti-tumor 
CD8
+ 
T cell response selectively in the bone.  
CD8
+ 
T cells have been described as critical inhibitors of bone metastases. Indeed, in mice, the 
alteration of CD8
+ 
T cell development after metastases implantation in the bone, or the 
deprivation of CD8
+ 
T cells, were reported to increase tumor growth (5)(6). Osteoclasts have 
been depicted to secrete chemokines that can attract CD8
+
T cells (33). However, the regulation 
of the BM burden by CD8
+ 
T cells seems totally independent of the osteoclast activity (6). Our 
study reveals that the cancer cells per se can influence both the recruitment and the cytotoxic 
activity of the CD8
+ 
T cells in the bone. Moreover, the ability of the BCa metastases to condition 
the immune response in the bone can be in part orchestrated by the levels of expression ERRon 
the BCa and potentially to the sensitivity of metastases to the ERR ligand(s). The selective 
effects of ERRexpression in BCa on the tumor burden of BM and anti-tumor response in the 
bone strongly suggest that unlike the lung, the bone could constitute a microenvironment with 
high levels of the ERRligand(s) that so far remain uncharacterized. Another alternative is that 
in the lung, but not the bone could be highly enriched in inhibitors of ERRsignaling or 
negative regulators of ERR expression that remain to be identified. Thus, the ability of the 
metastases to induce or not a potent immune response maybe dictated by both the tumor per se 
and the microenvironment where it is anchored. In the case of BCa cells, we propose to place 
ERRat the core of this interplay between metastases and their new microenvironment 
In addition to increasing the recruitment of activated CD8
+ 
T cells to the bone, the over-
expression of ERRon BCa cells also decreased their ability to produce high amounts of TGF-
3. Depletion experiments confirmed that CD8+ T cells are key anti tumor immune cells whose 
activation and recruitment are controlled by the levels of ERR expression on BM. All forms of 
TGF- have been reported as potent immune-regulators and share a common receptor (34). While 
TGF-1 is predominant in the immune system, TGF-3 is mainly produced by muscles, bones 
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but also by various cancer cells (35). The repression of TGF-3 production in ERR BCa cells, 
subsequently affects TGF- signaling in CD8+ T cells present in the bone. TGF- signaling 
represses the expression of numerous transcription factors associated with cytotoxicity, as well as 
T-Bet a key inducer of IFN- (36). Therefore, over-expressed ERR BCa cells that settle in the 
bone are unable to sustain an immunosuppressive microenvironment based on high levels of 
TGF- signaling in T cells and repression of cytotoxic program and IFN- production. 
Interestingly IFN- also contributes to the suppression of BM. Indeed, IFN- has been reported to 
reduce both RANKL expression and osteoclast formation, counterbalancing the aberrant bone 
resorption which facilitates tumor growth (37). Concomitantly, inhibition of bone resorption also 
leads to the decrease in TGF- release from the bone matrix (4), thus potentially contributing to 
amplifying the activation of T cells including their production of IFN-.  
It is likely that effector CD8
+
T cells that reach the BM have previously been primed in the 
draining lymph nodes or by the spleen-presenting antigens from the primary tumor and/or the 
metastases. As in the primary tumor, the activated CD8
+
T cell population in contact with the BM 
is actually heterogeneous and composed of cells recently activated and activated memory cells. 
Interestingly, in both mice and humans, the fraction of CD8
+
T cells that expresses CCR6 and 
CCR4 has been depicted to rapidly mount an efficient response, corresponding to activated 
/memory T cells (28). Once implanted in the bone, we found that the BCa over-expressing ERR 
have unique ability to sustain high expression of CCL17 and CCL20 and low expression of TGF-
3, thus attracting the activated/memory CD8+T cells whose their anti-tumor cytotoxic function is 
magnified by the lack of repression by TGF- signaling.  
In conclusion, this study assigns an unsuspected role for ERRexpression in BCa on the 
bone immune system that conditions the BM growth outcome, providing the mechanistic basis for 
understanding how ERRexpression in BCa can impact the bone microenvironment and reduce 
BM growth. ERR seems to appear at the core of this interplay between BCa metastases and their 
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new environment, integrating signals from the microenvironment to develop an efficient anti-
tumor response. Therefore, we propose to consider ERRexpression on BCa, as a biomarker 
predictive of BM response to immunotherapies and /or as a good prognosis marker in BM 
progression once established, opening the path towards to the clinical use of ERRagonist to 
relieve patients with ERR positive BM after primary tumor resection.  
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Table and Figure legends  
 
Fig. 1: Inhibition of BM development by ERR overexpression in BCa.  
(A-N), 4T1-CT, 4T1-ERRor 4T1-CT(af2) and 4T1-ERRAF2 cells were inoculated into 
BALB/c mice. 13-15 days post-inoculation, osteolytic lesions were analyzed. (A) Representative 
radiography. The osteolytic regions are delimitated by dash lines. (B) Graphs illustrate the mean 
size (mm
2
) ± SEM of osteolytic lesions (n=10 mice per group, Mann-Whitney, osteolysis: P < 
0.0001: 4T1-ERR versus CT). (C, D) Three-dimensional microCT reconstruction representation 
of tibiae in sagittal sections (C) and cross sections (D) following the cutting of the bone along the 
plane illustrated by the dashed lines in C. (E) Graphs illustrate the mean of the % of Bone 
Volume/Tissues Volume ± SEM (n=10, Mann-Whitney, BV/TV: P < 0.0001 for 4T1-ERR 
versus CT). (F) Histological images of bone sections after Goldner’s Trichrome staining. Tumors 
are delimitated by dash lines and * indicate the bone marrow. (G) Graphs illustrate the mean of % 
of Tumor Burden /Soft Tissues Volume ± SEM (n=10, Mann-Whitney, TB/STV: P < 0.0001 for 
4T1-ERR versus CT). (H-N) Respective representation and quantification of clones expressing a 
dominant-negative form (4T1-ERRAF2) with their controls clones (4T1-CTaf2): osteolytic 
lesions (n=9, Mann-Whitney, osteolysis: P < 0.0006: ERRAF2 versus CT (af2)) (H, I), % of 
Bone Volume/Tissues Volume ± SEM (n=9, Mann-Whitney, BV/TV: P < 0.0006 for 4T1-
ERRAF2 versus CT(af2)) (J-L) and % of Tumor Burden /Soft Tissues Volume ± SEM (n=9, 
Mann-Whitney, TB/STV: P < 0.0002 for 4T1-ERRAF2 versus CT(af2)) (M, N). 
 
Fig. 2: Overexpression of ERR in BCa cells has no impact on lung metastases development. 
(A) Histological analysis assessment of lung of mice 15 days post-cell injection after H&E 
coloration. Metastasis are marked with * (B) Graph illustrate the numbers of LM counted on 3 
representative sections at different levels of deepness (n=6). (C-F) Lungs from the same mice used 
to quantify BM (Fig.1) were crushed and cells released were cultured for 2 weeks. (C and E) are 
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representative pictures of LM colonies and (D and F) are graphs that illustrate the mean of number 
LM colonies formed for all mice ± SEM (n=6, Mann-Whitney, TB/STV: P>0.05). (G) Graph 
illustrates the mean ERRexpression in LM cell colonies after 2 weeks of culture. Semi-
quantitative PCR was performed in triplicate on n=3 animals (unpaired t-test: P < 0.0001) and 
normalized against the ribosomal protein gene L32 (mean ±SEM).  
 
Fig. 3: Overexpression of ERR in BCa cells promotes CD8+ T cytotoxic function.  
Cells suspensions were prepared from metastatic legs (bone) (A, C, D-F) or lungs (B, C) of mice 
(n=4) inoculated with 4T1-CT or 4T1-ERR cells. (A-B) Flow cytometry contour plots of CD45+ 
hematopoietic cells, illustrating the proportion of T cells (CD3
+
), B cells (CD19
+
) and CD4/CD8 T 
cells and graphs representing the percentage of cells in the bone (A) (mean ±SD, n = 4, student t-
test ** P < 0.001, *** P < 0.0001) and in the lungs (B). (C) Flow cytometry contour plots 
illustrating the production of FasL, LAMP-1, Granzyme A and B and IFN in CD8+ T cells. (D) 
Graphs demonstrate the percentage of cells and (E) their absolute numbers. (F, G) Fluorescent 
micrographs of sections of 4T1-CT or 4T1-ERR-expressing bone after TUNEL assay and 
enlarged views of dashed rectangles. Apoptotic cells are shown in red and the cell nucleus in blue 
after DAPI staining. (G, H) Scale bar=50m, T: tumor, GP: growth plate with apoptotic 




T cell depletion restore 4T1-ERR BM progression.  
4T1-ERR cells injected mice were treated with anti-CD8 antibodies every two day once 
osteolytic lesions occur ie at day 10 based on radiograhy (A) Flow cytometry analysis confirming 
the CD8
+
 T cell-depletion in the bones.  (B) Radiography, illustrating representative osteolytic 
lesions 18 days post- 4T1-ERR cells inoculation. The osteolytic regions are delimitated by dash 
lines. (C) Three-dimensional microCT reconstruction representation of tibiae in sagittal sections 
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(C) and cross sections (D) following the cutting of the bone along the plane illustrated by the 
dashed lines in C. (E) Graphs illustrate the mean of the % of Bone Volume/Tissues Volume ± 
SEM (Mann-Whitney, BV/TV: P =0.0037). 
 
Fig. 5: Ccl17 and Ccl20 up-regulation by ERR in BCa cells. 
(A) Heat map representative of cytokine, chemokine and growth factor mRNA expression in 4T1-
ERR and 4T1-CT cells, normalized against Ppia, Actb and Rplp0 expression. (B-D) Graph 
illustrates the relative gene expression after RT-PCR performed on triplicate samples and 
normalized against the ribosomal protein gene L32 (mean ± SEM). (B) 4T1-ERR, 4T1-CT or 
4T1-ERRAF2, 4T1-CT(af2) cells were analyzed (n=2, ANOVA: P < 0.0001 for Ccl17 and 
Ccl20, unpaired t-test P=0.0007 (Ccl17), P = 0.0005 (Ccl20) (4T1-ERR) and P = 0.0004 (Ccl20) 
4T1-ERRAF2 versus 4T1-CT). (C-D) 4T1-ERR and 4T1-ERRAF2 cells were cultured for 24 
hours with the inverse-agonist C29 (5 M) (unpaired t-test, P = 0.0005 and P = 0.0034 for Ccl17 
and Ccl20, respectively). (E) Tumor cell colonies obtained after crushing bones extracted from 
mice (n = 3) bearing either 4T1-ERR or 4T1-CT lesions and cultured during 4 weeks were 
analyzed (unpaired t-test P = 0.0059 (Ccl17), P < 0.0001 (Ccl20) and P < 0.0001 (ERR)). (F) 
Immunostaining for Ccl17 and Ccl20 on bone section colonized by either 4T1-ERRor 4T1-CT 
cells. Bar = 200 m, T: tumor, GP: growth plate. (G) Representative flow cytometry contour plot 
illustrating the expression of CCR4 and CCR6 on CD8
+
 T cells from bones colonized with either 
4T1-ERRor4T1-CT cells. All in vitro and ex vivo analyses were repeated at least twice. Data are 
plotted as mean ± SEM.  
 
Fig. 6: Over-expression of ERR in BCa inhibits Tgf-3 expression and affects TGF- 
signaling in CD8
+
T cells. (A) Overlay of the Minimal Network (containing 101 proteins) with 
extracted information from the Gene-Ontology-consortium of proteins involved in the immune 
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system process, as well as to create “Minimal Network specific to immune response to tumor” 
(containing 52 proteins). (B, C) Potential new regulators of ESRRA, including VCAM1, MACF1, 
HUR and TGF-3, were identified through systematic shortest path definition of crosstalks. (D-E) 
Graphs illustrating the relative gene expression after RT-PCR performed on triplicate samples and 
normalized against the ribosomal protein gene L32 (mean ± SEM). (D) 4T1-ERR, 4T1-
ERRAF2, 4T1-CT and 4T1-CT(af2) cells were analyzed (ANOVA: P < 0.0001 and unpaired t-
test P < 0.0001 4T1-ERR versus 4T1-CT, P = 0.0009 for 4T1-ERRAF2 versus 4T1-CT(af2)). 
(E) Tumor cell colonies obtained after crushing bones extracted from mice (n = 3) bearing either 
4T1-ERR or 4T1-CT lesions and cultured during 4 weeks were analyzed (unpaired t-test P = 
0.0056). (F) Immunostaining for Tgf-3 on bone section colonized by either 4T1-ERR 4T1-CT 
cells or 4T1-CT(af2) and 4T1-ERRAF2 cells. Bar = 200 m, T: tumor, GP: growth plate. (G) 
4T1-ERR cells were cultured for 24 hours with the inverse-agonist XCT-790 (1 M) (unpaired t-
test, P = 0.0007). Data are plotted as mean ± SEM. (H) RT PCR performed on mRNA of MCF7 
and B02 clones. Mean of three different cultures for each MCF7 clones are shown for TGF-3 
(unpaired t-test P = 0.0218 MCF7-ERR versus MCF7-CT; B02 clones: ANOVA: P = 0.0027, 
unpaired t-test P = 0.007: B02-ERR versus B02-CT).  (I) Representative flow cytometry 
histogram plot illustrating the phosphorylation of SMAD2/3 in CD8
+
 T cells from bones colonized 
with either 4T1-ERR cells or 4T1-CT. The percentage of positive cells is illustrated. These ex 
vivo data are representative of 2 experiments with 3-4 mice per group. All in vitro analyses were 
repeated at least twice.  
 
Table 1: Correlation in clinics in BCa patients. (A, B) Meta-analysis of public datasets 
(GSE12276-GSE2034-GSE2603) (n=248) revealed a positive correlation between the 
expression of ESRRA and CCL17 and CCL20 and a negative correlation with TGF-3 
expression levels in luminal (A) and triple-negative (B) breast tumors. Correlation scores were 
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Abbreviations used in this paper: ANOVA: analysis of variance; BM: Bone Metastases; B 
BV/TV: Bone Volume/Tissues Volume; CCL17-CCL20: Chemokine (C-C motif) ligand 17, 20; 
CCR4 and CCR6: C-C chemokine receptor type 4 and 6; ERR: estrogen receptor-related receptor; 
LAMP-1: Lysosome-associated membrane glycoprotein-1; LM: Lung Metastases; OCs: 
osteoclasts; RANKL: receptor activator of nuclear factor kB ligand; RT: reverse transcription; 
PCR: polymerase chain reaction; PMN-MDSC: Poly-MorphoNuclear Myeloid Derived 
Suppressor cells; TNBC: Triple-negative breast cancer; TGF-: Transforming Growth Factor 
Beta; TB/STV: Burden /Soft Tissues Volume. 
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